42 results about "SMN1" patented technology

Provided are tricyclo-DNA (tc-DNA) AON and methods employing tc-DNA AON for modifying splicing events that occur during pre-mRNA processing. Tricyclo-DNA (tc-DNA) AON are described that may be used to facilitate exon skipping or to mask intronic silencer sequences and/or terminal stem-loop sequences during pre-mRNA processing and to target RNase-mediated destruction of processed mRNA. Tc-DNA AON described herein may be used in methods for the treatment of Duchenne Muscular Dystrophy by skipping a mutated exon 23 or exon 51 within a dystrophin gene to restore functionality of a dystrophin protein; in methods for the treatment of Spinal Muscular Atrophy by masking an intronic silencing sequence and/or a terminal stem-loop sequence within an SMN2 gene to yield modified functional SMN2 protein, including an amino acid sequence encoded by exon 7, which is capable of at least partially complementing a non-functional SMN1 protein; and in methods for the treatment of Steinert's Myotonic Dystrophy by targeting the destruction of a mutated DM1 mRNA comprising 3′-terminal CUG repeats.

The invention discloses a fluorescent quantitative PCR kit for detecting the copy number of a virulence gene of human spinal muscular atrophy. The fluorescent quantitative PCR kit comprises amplimersand fluorescent probes, wherein the amplimers consist of a pair of shared primers for specific amplification of the seventh exon of SMN1 and SMN2 genes, a pair of shared primers for specific amplification of the eighth exon of the SMN1 and SMN2 genes, and a pair of specific primers for specific amplification of a reference gene, i.e., a CFTR gene; and the fluorescent probes consist of a fluorescent probe for specific detection of the seventh exon of the SMN1 gene, a fluorescent probe for specific detection of the eighth exon of the SMN1 gene, a fluorescent probe for specific detection of the seventh exon of the SMN2 gene, a fluorescent probe for specific detection of the eighth exon of the SMN2 gene and a fluorescent probe for specific detection of the reference gene CFTR. The fluorescentquantitative PCR kit for detecting the copy number of the virulence gene of human spinal muscular atrophy is directed at problems and insufficiencies in quantitative detection of the copy numbers of human motoneuron genes and is rapid and simple in detection and reliable in detection results.

The invention belongs to the technical field of in-vitro nucleic acid detection and especially relates to a relative quantitative detection method of human motor neuron gene copy numbers and a kit thereof. According to the invention, specific primers and probes to the seventh and eighth exons of SMN1 and SMN2 genes and reference gene RPP40 are respectively designed; at the same time, qualitative detection primers and probes are also designed for three hot spot mutations of Y272C, 11bp-DUP and 4bp-DEL of the SMN1 gene. The kit comprises a container containing detection primer and probe compositions, a reference container and a PCR reaction liquid container. Relative quantitative determinations to the copy numbers of the seventh and eighth exons of SMN1 (in the first and second PCR reactions) and the seventh and eighth exons of SMN2 (in the third and fourth PCR reactions) and qualitative detection to the three hot spot mutations of Y272C, 11bp-DUP and 4bp-DEL (in the fifth PCR reactions) are respectively performed by 5 independent PCR reactions. The kit is strong in specificity, high in sensitivity, convenient, fast and applicable to large-scale popularization and application.

The invention discloses a primer and a probe for screening spinal muscular atrophy (SMA) genes and a using method of the primer and probe, belonging to the technical field of biology. The invention discloses eight combinations of the primer and probe for screening survival motor neuron genes 1 (SMN1), and the primer and probe can be effectively applied to screening the SMN1. Meanwhile, the invention also discloses sixteen groups of combinations of the primer and probe for screening survival motor neuron genes 2 (SMN2), as well as application in fetal SMA gene screening by utilizing the primer and probe for screening the SMN1 and the primer and probe for screening the SMN2. According to the primer and probe provided by the invention, the SMA genotypes of adults and fetuses can be detected at high efficiency.

The invention discloses a detection kit and a method for copy number of spinal muscular atrophy pathogenic gene SMN1 based on a real-time fluorescence quantitative PCR (Polymerase Chain Reaction) technique. The detection kit comprises specific primers SMN1-F (SEQ ID NO.1) and SMN1-R (SEQ ID NO.2) modified by NO.7 exon locked nucleic acid of a pair of target genes SMN1, an SMN1 detection probe (SEQID NO.3), an SMN2 gene closed probe SMN2-B (SEQ ID NO.4) modified by SMN-P locked nucleic acid and 3'end C3Spacer, gene primers ALB-F (SEQ ID NO.5) and ALB-R (SEQ ID NO.6) of a reference gene ALB andan ALB detection probe ALB-P (SEQ ID NO.7). The amplification specificity and amplification efficiency of the SMN1 gene are enhanced by using locked nucleic acid modification; a stable reaction system for double amplification of the target genes and the reference gene is established by using a multi-PCR principle and optimizing reaction systems and conditions, and further quantitative accuracy and reliability of the copy number of the SMN1 can be ensured; good repeatability and high operability are obtained.

The invention provides a method for detecting SMN1 mutation based on the high throughput sequencing technology and a corresponding kit, wherein the used primer composition comprises primers of the No. 7 exon of the specific amplification SMN1 gene and primers of close linkage SNP of the specific amplification SMN1 gene within the upstream and downstream 3Mb range. The method disclosed by the invention has the advantages of universality, multi-site SNP sequencing, high flux, low cost, and high sensitivity and specificity.

The disclosure concerns methods and compositions for obtaining reliable copy numbers of highly homologous gene(s) using next generation sequencing. The methods determine whether or not an individual is a carrier of an autosomal recessive gene mutation using a determination of copy number of two genes, in specific embodiments. In at least some cases, an individual is identified whether or not he or she is a carrier or affected for a genetic defect in SMN1, wherein the defect is associated with spinal muscular atrophy.

The invention relates to the field of genetic testing, and specifically relates to a kit used for detecting the copy number of survival genes of human motor neurons. According to the kit used for detecting the copy number of the survival genes of the human motor neurons, a multifluorescent polymerase chain reaction (PCR) method is adopted for detecting the copy number of the survival genes of thehuman motor neurons; and specific primers and probes for exons 7 and 8 of SMN1 gene, exons 7 and 8 of SMN2 gene, exon 6 of SMN gene and internal reference gene cystic fibrosis transmembrane regulator(CFTR) are separately designed. The kit is smartly designed, so that, relative quantifying can be separately performed on the copy number of the exons 7 and 8 of the SMN1 gene, the exons 7 and 8 of the SMN2 gene as well as the exon 6 of the SMN gene by adopting 3 independent PCR reactions. The kit is easy to operate, strong in specificity and excellent in sensitivity. Thus, the result of the copynumber of the exon 6 of the SMN gene can be improved in terms of accuracy; so that, the kit is more suitable for clinical classifying of patients with spinal muscular atrophy and screening of carriers.

The invention discloses a probe for detecting common genetic diseases, a gene chip, a preparation method and application. The preparation method comprises the following steps of according to genes ofthalassemia, phenylketonuria, spinal muscular atrophy, hepatolenticular degeneration, pseudomuscular hypertrophy, glycogen storage disease Type II, methylmalonic academia, methylmalonic aciduria-accompanied type cysteine peptiduria Type cb1C, and oculocutaneous albinism Type 1, constructing a target capturing area, and designing a capturing probe, wherein the target capturing area comprises all globin genes, important regulating areas, deleted mutation breakpoints and SNP (single nucleotide polymorphism) sites of alpha and beta genes, and SMN1, PAH, ATP7B, DMD, GAA, MUT, MMACHC and TYR genes.The probe for the gene mutation of common genetic diseases can be designed according to the related genes of nine types of genetic diseases, and the prepared probe can be used for detecting the nine types of genetic diseases, and be suitable for large-scale population diagnosis and screening.

The invention discloses a detection kit for human survival motor neuron genes SMN1 and SMN2, and a method. The kit comprises an SMN1 main reaction liquid, an SMN2 main reaction liquid, an enzyme mixed liquid, 0-copy quality control, SMN1 single-copy quality control, SMN1 two-copy quality control, SMN2 single-copy quality control and SMN2 two-copy quality control, wherein the SMN1 main reaction liquid comprises a detection primer of the gene SMN1 and an inner reference primer of the SMN1; and the SMN2 main reaction liquid comprises a detection primer of the gene SMN2 and an inner reference primer of the SMN2. According to the kit, a PCR melting curve method is adopted, the change of a fluorescence signal value during a double-strand DNA melting process is detected in real time, target genes and inner reference genes generate different dissolution peaks according to the difference of different amplification product quantities, and then the copy numbers of the genes SMN1 and SMN2 are judged through software processing. The kit and the method which are disclosed by the invention are high in detection result accuracy, high in sensitivity, less in detection time consumption and low in cost.

The invention relates to a method for detecting a genetic disease gene and particularly discloses a method for detecting a spinal muscular atrophy virulence gene. The method comprises the following steps: 1, performing enrichment processing on SMN1 and SMN2; 2, preparing a nanopore sequencing library for sequencing; 3, sequencing by a sequenator; and 4, performing clinical report evaluation on the obtained sequence file. The method is convenient to use, low in cost and can effectively and accurately detect the copy number of the spinal muscular atrophy virulence gene, the small segment insertion and deletion, the point mutation, the noncoding region mutation and even the gene translocation, and brings help and breakthrough for the clinical diagnosis and scientific research on the spinal muscular atrophy.

The invention relates to a spinal muscular atrophy pathogenic gene detection kit based ona melting curve analysis, and relates to a pathogenic gene detection kit, which comprises an upstream primer F1 and a downstream primer R1 for amplifyingexon7 of SMN1 and SMN2 genes; an upstream primer F2 and a downstream primer R2 for amplifying exon4 of an internal reference CFTR gene; and a fluorescent probe for detection. In a single-tube PCR system, the copy number of exon7 of the SMN1 gene as a main pathogenic gene of SMA can be quantitatively detected, the sample genotype can be known by a fluorescence PCR melting curve analysis after PCR amplification is finished, the whole operation is completed in 2 to 3h, is simple and rapid, and is short in time-consuming; the homogeneous detection and closed tube operation are carried out; the detection flux is high; the detection specificity is high, and the results are easy to interpret. The detection kit can be rapidly and convenientlyapplied to large-scale population screening of the SMA pathogenicgene, and is especially suitable for prenatal, premaritaland pre-pregnancy screening and genetic diagnosis of patients.

The invention relates to detection primers for gene mutation related to spinal muscular atrophy and its application. The detection primers comprise a pair of primers specifically detecting the exon No.7 of a SMN1 gene, and three pairs of reference gene primers, wherein the nucleotide sequences of the pair of primers are SEQ ID No. 1 and SEQ ID No. 2, respectively, and the nucleotide sequences of the three pairs of reference gene primers are SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, and SEQ ID No. 8, respectively. The above 4 pairs of primers are utilized for simultaneous fluorescent short-segment multiplex PCR detection of to-be-detected samples and normal samples; fluorescent signal data is collected; and whether mutation exists in the DNAs of the to-be-detected samples is analyzed. The invention also relates to a detection kit. The primers and kit provided by the invention are ingenious in design, simultaneously detect the SMN1 gene and a plurality of pairs of reference genes and compare the SMN1 gene with the plurality of pairs of reference genes, thereby more accurately reflecting the mutation of to-be-detected genes.

A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis under a optimized separation condition. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon.

The invention provides a method and system for determining whether No.7 exon deletion exists in an SMN1 gene of samples to be tested or not. Compared with the prior art, the method and system providedby the invention have the advantages that in an aspect of No.7 exon deletion detection of the SMN1 gene, the sensitivity and the specificity are obviously improved; heterozygous deletion samples andhomozygous deletion samples can be effectively distinguished; and when the proportion of normal samples in the batch (No.7 exons of the SMN1 gene and the MSN2gene are respectively 2 copies) is small,the detection precision is greatly improved by selecting a control sample set.

The invention relates to the technical field of molecular biology genes and medical field and particularly discloses a method and primer group for detecting SMN1 gene mutation. Nucleotide sequences ofdeletion mutation regions of exons 7 and 8 of an SMN1 gene related to spinal muscular atrophy (SMA) are analyzed, corresponding primers are designed, multiple PCR amplification is performed on specific sites of sample genome DNA, and finally, detection is carried out by an Ion Torrent semiconductor chip sequencing technology. The detection method of the invention has the advantages of large flux,high specificity and sensitivity, result stability, good repeatability, high detection speed and the like, a new way which is rapid, reliable and accurate is provided for detection, test, analysis and evaluation of the SMA in the aspect of genetics, and the theoretical basis is provided for clinical diagnosis of the disease.

The invention relates to a simple and convenient method and specific process for detecting SMA. The key point of the technical scheme is that DNA sequencing is carried out on SMN intron 6-exon 8 in the PCR products; if exons 7 and 8 of SMN1 are homozygous deletions, only homozygous peaks of +6T on exon 7 of SMN2 and +245A on exon 8 of SMN2 are found; the method can be used for screening the molecular background of the copy number of the same SMN2 and the phenotypic deviation of the SMA; the +6 position on the exon 7 and +245 position on exon 8 of SMN appear nesting peak; if the phenotype is normal, the subject is normal people; if the subject is a patient, the point mutation of SMN1 can be preliminarily screened. The main application is as follows: the gene level of 98.6 percent of patients can be determined; the molecular background of the same SMN2 copy number and SMA phenotypic deviation can be screened; the remaining few SMA patients with loss of heterozygosity and point mutation are able to screen for point mutations in SMN1. The method is very suitable for basic medical units and is beneficial to further research on the mechanism of the disease.

Provided herein are methods and compositions for the detection of silent carriers of chromosomal deletion alleles in a human subject using haploid cells (e.g., sperm cells or egg cells) derived from the subject. The methods provided herein allow for the detection of silent (2+0) carriers of SMA, where the individual has a deletion of the SMN1 gene on one chromosome 5 homolog and two or more copies of the SMN1 gene on the other chromosome 5 homolog.

The invention provides a detection method of an SNP (single nucleotide polymorphism) site of an SMA gene. The method comprises the following steps of (S10) performing a polymerase chain reaction (PCR), and amplifying a nucleic acid fragment including an SNP site; (S20) performing a dephosphorylation reaction on the nucleic acid fragment; (S30) performing an extension reaction on the nucleic acid fragment, wherein an extension primer is used for identifying the position of the SNP site, and single nucleotide which is in base complementarity with the SNP site is extended at a 3' end of the extension primer so that an extended extension primer is obtained; (S40) performing a purifying reaction to purify the extended extension primer; and(S50) detecting the size of the molecular weight of theextended extension primer, and according to the size of the molecular weight, determining the kind of bases of the extended single nucleotide, so that according to the kind of the bases of the SNP site in the SMA gene (including an SMN1 gene and an SMN2 gene), determining whether SMN1 gene homozygosis deletion occurs or not.